Immunohistochemistry (IHC) of GBM samples revealed that MET404 expression was spatially correlated with YTHDF2 expression (Fig. 2k), and high MET404 expression predicted worse overall survival of GBM patients (Fig. 2l). Here, YTHDF2 is linked to glioblastoma.